treatment with focal HIFU

PROCEDURE2 trials

Sponsors

Hospices Civils de Lyon

Conditions

Prostate Cancer

Phase 2

Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer

CompletedNCT03568188

Hospices Civils de LyonProstate Cancer

Start: 2018-09-28End: 2026-02-09Updated: 2026-02-24

Phase 3

Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer

Active, not recruitingNCT03531099

Hospices Civils de LyonProstate Cancer

Start: 2018-10-02End: 2026-10-02Updated: 2025-06-22

Related Papers

Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.

Journal of Clinical Oncology2021-05-207 citations

Chemotherapy induced profound neutropenia (PN) in patients (pt) with breast cancer (BC) after chemotherapy and plinabulin (Plin) plus pegfilgrastim (Peg) combination versus (vs) peg alone: Final phase 3 results from protective-2 (BPI-2358-106).

Journal of Clinical Oncology2021-05-203 citations

Impact of adding plinabulin to pegfilgrastim for the prevention of TAC chemotherapy (Chemo) induced neutropenia (CIN), on patient quality of life (QoL).

Journal of Clinical Oncology2021-05-201 citations